Canaccord lowered the firm’s price target on TriSalus Life Sciences (TLSI) to $11 from $12 and keeps a Buy rating on the shares. The firm believes TriSalus has the foundation of a strong medical device business with a commercial footprint and catalysts to support it including new product launches and clinical data.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TLSI: